It's in the Cup

When we formulated SYC Defense Protocol, we looked at every ingredient with evidence for cold prevention — including green tea. The research on brewed green tea is meaningful. We decided not to include a concentrated green tea extract in the capsule. Here's why that distinction matters, and where green tea belongs in your protocol instead.

Green tea as a beverage is one thing. A concentrated green tea extract in a capsule is another. The research that caught our attention was conducted on brewed green tea — not on an isolated extract. Something in that cup appears to reduce respiratory infection risk. The leading hypothesis points to a family of compounds called catechins, particularly one known as EGCG. But brewed green tea contains hundreds of compounds — polyphenols, flavonoids, theanine, minerals — and no one has cleanly isolated a single ingredient as the responsible agent in human trials. The catechin hypothesis is compelling. It is also still a hypothesis.

The supplement industry took that hypothesis, concentrated one compound into extract form, and created a product. In doing so, they introduced a risk the beverage never had. In rare cases, concentrated green tea extract has caused serious liver injury. We cannot predict who is vulnerable. There is no screening test. And when we cannot screen for a real risk, we do not include the ingredient — even when the beverage it was derived from shows meaningful research. The ingredients we chose for SYC Defense Protocol may support your immune function. We are confident in that "may." We are equally confident that the risk is little to none. That is our governing principle: evidence of benefit does not override unacceptable risk.

So where does green tea live in your protocol?

Two places. First, brew it regularly as part of your year-round immune strategy — the same daily commitment as SYC Defense Protocol. A little honey to sweeten it is a fine choice. Second, when you do get sick, green tea becomes your hot liquid of choice for sore throat and cough management. At that point, add honey — not just for taste. Evidence supports honey for cough relief, particularly in those first few days when symptoms are at their worst. Warm liquid, the right ingredients, doing exactly what they are designed to do.

We chose not to include a concentrated extract of something the research studied in a cup — as nature made it. We are recommending you follow nature's lead and do the same.

The Principle

Every ingredient in SYC Defense Protocol was selected because the evidence supports its potential to help — and because the risk is little to none. Both gates matter equally.

Green tea earns its place in your protocol. In a cup — not in our capsules.

Want to go deeper?

The clinician version isn't just for doctors. It's the same topic, written for physicians — the full reasoning, nothing simplified. You're allowed to read it. Read the clinician version →

The most rigorous comparison available — Zhu et al., EClinicalMedicine, 2025, 107 RCTs, 101,751 adults — identified catechins as one of the most effective interventions for reducing respiratory infection incidence among the oral nutritional supplements evaluated: relative risk 0.79, 95% confidence interval 0.66 to 0.95, high certainty. That is a meaningful signal. But where the evidence comes from matters as much as the number itself.

The studies were conducted on brewed green tea consumption and dietary catechin intake — not on isolated EGCG extract. Brewed green tea contains hundreds of bioactive compounds. The catechin hypothesis is the leading mechanistic explanation, supported by in vitro and animal model data showing EGCG inhibits viral binding, blocks RNA polymerase activity, and enhances mucosal IgA production. But no human RCT has cleanly isolated EGCG as the sole responsible agent. The industry took a beverage association, attributed it to one compound, concentrated that compound into extract form, and created a product — without establishing that the extract performs the way the beverage does, and without the safety profile the beverage has demonstrated over centuries of consumption. We do not know exactly which of nature's compounds in that cup did the work. Concentrating one of them was a hypothesis, not a proof.

In doing so, the industry introduced a risk the beverage never had. The Drug-Induced Liver Injury Network registry documents idiosyncratic immune-mediated hepatotoxicity from concentrated green tea extract. The HLA-B*35:01 association has been recognized by AASLD — present in 72% of green tea extract hepatotoxicity cases, consistent with an immune-mediated mechanism. The allele can be typed, but no HLA screening is built into consumer supplement use — in a real-world DTC population there is no practical way to identify a vulnerable buyer before injury occurs. The EFSA has identified doses at or above 800 mg EGCG per day in supplement form as associated with statistically significant transaminase elevations. You have an extract resting on an unproven extraction hypothesis and carrying an unscreenable, potentially serious hepatotoxicity profile in a real-world DTC population.

We evaluated it under the same framework as every other candidate on this platform: possible benefit with little to no risk. It passed the benefit gate. It failed the risk gate. The extract stays out. The tea goes in.

The Recommendation

The decision was not close. Evidence of benefit does not override unscreenable risk in a DTC population, and that principle applies without exception. What we are recommending instead is the form the evidence actually studied — brewed green tea, at a minimum of one cup daily as part of your patient's year-round protocol, and as the hot liquid of choice during acute illness with honey. The benefit tracks with intake — one cup daily is the floor, and a second seems to add to it. Whatever in that cup does the work is there. The hepatotoxicity risk is not. If your patient asks why one of the most compelling cold-prevention signals in the 2025 network meta-analysis isn't in the capsule, this is the answer. It's in the cup.

Clinical Bottom Line

Strong prevention signal in the beverage. Unproven extraction hypothesis in the capsule. Unscreenable hepatotoxicity in the extract. Recommend brewed green tea, not concentrated extract — the form the evidence was actually built on.